Carmelo Nucera, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 29 | 2023 | 2332 | 4.760 |
Why?
|
| Proto-Oncogene Proteins B-raf | 18 | 2023 | 2054 | 2.440 |
Why?
|
| Pericytes | 5 | 2023 | 293 | 2.310 |
Why?
|
| Indoles | 8 | 2015 | 1832 | 1.050 |
Why?
|
| Carcinoma | 6 | 2016 | 2330 | 1.040 |
Why?
|
| Sulfonamides | 8 | 2015 | 1975 | 0.940 |
Why?
|
| Neovascularization, Pathologic | 6 | 2021 | 2644 | 0.770 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2021 | 72 | 0.740 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2021 | 184 | 0.730 |
Why?
|
| Phenylurea Compounds | 2 | 2021 | 529 | 0.680 |
Why?
|
| Lipogenesis | 1 | 2021 | 214 | 0.650 |
Why?
|
| Mutation | 13 | 2022 | 30045 | 0.620 |
Why?
|
| RNA, Untranslated | 1 | 2021 | 459 | 0.580 |
Why?
|
| Quinolines | 1 | 2021 | 764 | 0.530 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2018 | 318 | 0.520 |
Why?
|
| Thrombospondin 1 | 2 | 2023 | 257 | 0.500 |
Why?
|
| Genes, p53 | 2 | 2015 | 712 | 0.500 |
Why?
|
| Genes, p16 | 1 | 2015 | 160 | 0.500 |
Why?
|
| Gene Dosage | 3 | 2015 | 1218 | 0.500 |
Why?
|
| Angiogenic Proteins | 1 | 2015 | 101 | 0.490 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2018 | 629 | 0.470 |
Why?
|
| Iodine | 1 | 2016 | 288 | 0.470 |
Why?
|
| Hemangiopericytoma | 1 | 2014 | 71 | 0.460 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2021 | 5305 | 0.460 |
Why?
|
| Frameshift Mutation | 1 | 2015 | 392 | 0.450 |
Why?
|
| Micronutrients | 1 | 2016 | 381 | 0.450 |
Why?
|
| Cachexia | 1 | 2015 | 202 | 0.440 |
Why?
|
| Mutagenesis, Insertional | 1 | 2015 | 656 | 0.420 |
Why?
|
| Iodine Radioisotopes | 4 | 2023 | 1033 | 0.390 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 8545 | 0.360 |
Why?
|
| Antineoplastic Agents | 6 | 2021 | 13637 | 0.360 |
Why?
|
| Parietal Lobe | 1 | 2015 | 851 | 0.360 |
Why?
|
| Carcinoma, Papillary | 4 | 2022 | 785 | 0.340 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2015 | 1115 | 0.340 |
Why?
|
| Energy Metabolism | 1 | 2021 | 2881 | 0.340 |
Why?
|
| Disease Progression | 4 | 2018 | 13502 | 0.330 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2009 | 164 | 0.320 |
Why?
|
| Tumor Microenvironment | 5 | 2023 | 3874 | 0.310 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2021 | 3602 | 0.300 |
Why?
|
| Thyroid Hormones | 1 | 2010 | 404 | 0.290 |
Why?
|
| Mitochondria | 1 | 2021 | 3623 | 0.290 |
Why?
|
| Cell Line, Tumor | 10 | 2021 | 16979 | 0.290 |
Why?
|
| Leptin | 1 | 2015 | 1597 | 0.280 |
Why?
|
| Disease Models, Animal | 7 | 2023 | 18247 | 0.280 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 1886 | 0.270 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2015 | 2916 | 0.260 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2010 | 1171 | 0.260 |
Why?
|
| Thyroidectomy | 4 | 2015 | 907 | 0.260 |
Why?
|
| Hyperhomocysteinemia | 1 | 2006 | 118 | 0.250 |
Why?
|
| Embryonic Development | 1 | 2010 | 720 | 0.250 |
Why?
|
| Mice, SCID | 5 | 2015 | 2626 | 0.250 |
Why?
|
| Oncogene Proteins | 1 | 2009 | 718 | 0.240 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2006 | 276 | 0.240 |
Why?
|
| Hypoparathyroidism | 1 | 2006 | 136 | 0.240 |
Why?
|
| DiGeorge Syndrome | 1 | 2006 | 185 | 0.230 |
Why?
|
| Transcriptional Activation | 1 | 2010 | 1756 | 0.230 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2006 | 165 | 0.230 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 2047 | 0.230 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2023 | 5665 | 0.220 |
Why?
|
| Transfection | 4 | 2015 | 5775 | 0.220 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 3612 | 0.220 |
Why?
|
| Galectin 3 | 1 | 2005 | 240 | 0.210 |
Why?
|
| Mutation, Missense | 1 | 2010 | 2571 | 0.190 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 3798 | 0.190 |
Why?
|
| Mice | 12 | 2023 | 81509 | 0.190 |
Why?
|
| Valine | 2 | 2014 | 408 | 0.180 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 2824 | 0.180 |
Why?
|
| Signal Transduction | 6 | 2018 | 23441 | 0.180 |
Why?
|
| Cytokines | 1 | 2015 | 7392 | 0.170 |
Why?
|
| Immunohistochemistry | 5 | 2015 | 11073 | 0.170 |
Why?
|
| Neoplasm Metastasis | 2 | 2021 | 4912 | 0.150 |
Why?
|
| Humans | 32 | 2023 | 761423 | 0.150 |
Why?
|
| Animals | 14 | 2023 | 168441 | 0.140 |
Why?
|
| Thyroid Gland | 4 | 2012 | 1168 | 0.140 |
Why?
|
| Glutamic Acid | 2 | 2014 | 1176 | 0.140 |
Why?
|
| Mass Spectrometry | 2 | 2014 | 2192 | 0.130 |
Why?
|
| Blotting, Western | 2 | 2015 | 5036 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2015 | 127 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2016 | 3490 | 0.120 |
Why?
|
| Oxidation-Reduction | 1 | 2021 | 2230 | 0.120 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2015 | 613 | 0.120 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 9031 | 0.120 |
Why?
|
| Adenoma | 1 | 2005 | 2160 | 0.110 |
Why?
|
| Databases, Genetic | 1 | 2021 | 1742 | 0.110 |
Why?
|
| Aphasia | 1 | 2015 | 192 | 0.110 |
Why?
|
| Fatty Acids | 1 | 2021 | 1808 | 0.110 |
Why?
|
| Cell Proliferation | 4 | 2014 | 10441 | 0.100 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 1 | 2012 | 175 | 0.090 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 1827 | 0.090 |
Why?
|
| Brain Edema | 1 | 2015 | 604 | 0.090 |
Why?
|
| Craniotomy | 1 | 2015 | 741 | 0.090 |
Why?
|
| Lac Operon | 1 | 2010 | 237 | 0.090 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 384 | 0.090 |
Why?
|
| Mice, Inbred DBA | 1 | 2010 | 621 | 0.080 |
Why?
|
| Cell Movement | 2 | 2012 | 5203 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2011 | 473 | 0.080 |
Why?
|
| beta-Galactosidase | 1 | 2010 | 574 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2012 | 546 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2011 | 477 | 0.080 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 9418 | 0.080 |
Why?
|
| Models, Biological | 2 | 2018 | 9469 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 3810 | 0.080 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 856 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2009 | 319 | 0.080 |
Why?
|
| Vision Disorders | 1 | 2015 | 1088 | 0.080 |
Why?
|
| Benzenesulfonates | 1 | 2009 | 166 | 0.080 |
Why?
|
| RNA Interference | 3 | 2012 | 2831 | 0.080 |
Why?
|
| Apoptosis | 3 | 2015 | 9488 | 0.080 |
Why?
|
| Genotype | 2 | 2014 | 13009 | 0.080 |
Why?
|
| Cell Survival | 2 | 2015 | 5790 | 0.070 |
Why?
|
| Tissue Array Analysis | 1 | 2009 | 550 | 0.070 |
Why?
|
| Isoquinolines | 1 | 2009 | 352 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 3779 | 0.070 |
Why?
|
| Transgenes | 1 | 2010 | 1010 | 0.070 |
Why?
|
| Niacinamide | 1 | 2009 | 413 | 0.070 |
Why?
|
| Genes, Reporter | 1 | 2010 | 1529 | 0.070 |
Why?
|
| Amino Acid Substitution | 1 | 2010 | 1738 | 0.070 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 2016 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2016 | 3110 | 0.060 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 1613 | 0.060 |
Why?
|
| Cell Line | 3 | 2013 | 15605 | 0.060 |
Why?
|
| Phenotype | 2 | 2021 | 16606 | 0.060 |
Why?
|
| Genetic Engineering | 1 | 2010 | 933 | 0.060 |
Why?
|
| RNA, Small Interfering | 2 | 2012 | 3428 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2009 | 1626 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2011 | 2918 | 0.060 |
Why?
|
| Central Nervous System | 1 | 2010 | 1337 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2009 | 2510 | 0.050 |
Why?
|
| Thyroid Nodule | 1 | 2010 | 764 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 2811 | 0.050 |
Why?
|
| Graves Disease | 1 | 2003 | 238 | 0.050 |
Why?
|
| Thyroid Diseases | 1 | 2005 | 386 | 0.050 |
Why?
|
| DNA Copy Number Variations | 1 | 2010 | 2020 | 0.050 |
Why?
|
| Prognosis | 1 | 2021 | 29620 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2005 | 2265 | 0.050 |
Why?
|
| Staining and Labeling | 1 | 2005 | 1084 | 0.040 |
Why?
|
| Female | 11 | 2022 | 392581 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2011 | 8320 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2010 | 3612 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 5789 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 17912 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2009 | 2871 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2009 | 5868 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 3 | 2012 | 3589 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 9535 | 0.040 |
Why?
|
| Pyridines | 1 | 2009 | 2875 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 9277 | 0.030 |
Why?
|
| Aged | 5 | 2015 | 169235 | 0.030 |
Why?
|
| Male | 7 | 2012 | 360736 | 0.030 |
Why?
|
| Adult | 6 | 2022 | 221148 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 22163 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2009 | 58956 | 0.020 |
Why?
|
| Lung Neoplasms | 2 | 2011 | 13337 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2012 | 1647 | 0.020 |
Why?
|
| Pregnancy | 1 | 2010 | 29862 | 0.020 |
Why?
|
| Sicily | 1 | 2008 | 10 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2010 | 410 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2012 | 2748 | 0.020 |
Why?
|
| Microdissection | 1 | 2008 | 151 | 0.020 |
Why?
|
| Middle Aged | 5 | 2012 | 220826 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2012 | 1006 | 0.020 |
Why?
|
| Random Allocation | 1 | 2011 | 2394 | 0.020 |
Why?
|
| Multigene Family | 1 | 2010 | 1077 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2012 | 18964 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2009 | 41446 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2012 | 3093 | 0.020 |
Why?
|
| Geography | 1 | 2008 | 656 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2010 | 1088 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2010 | 1118 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 1706 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2008 | 632 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 2455 | 0.010 |
Why?
|
| Lasers | 1 | 2008 | 951 | 0.010 |
Why?
|
| DNA Primers | 1 | 2008 | 2820 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2011 | 2932 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 1405 | 0.010 |
Why?
|
| Cell Division | 1 | 2010 | 4466 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2012 | 2863 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2012 | 4278 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 4110 | 0.010 |
Why?
|
| Wound Healing | 1 | 2012 | 2803 | 0.010 |
Why?
|
| Neoplasms | 1 | 2010 | 22164 | 0.010 |
Why?
|
| Cost of Illness | 1 | 2010 | 1936 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 4575 | 0.010 |
Why?
|
| Zebrafish | 1 | 2012 | 3007 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 13449 | 0.010 |
Why?
|
| Weight Loss | 1 | 2011 | 2683 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2008 | 2914 | 0.010 |
Why?
|
| Protein Binding | 1 | 2012 | 9352 | 0.010 |
Why?
|
| Body Weight | 1 | 2010 | 4618 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 17644 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 2826 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 8529 | 0.010 |
Why?
|
| Patient Selection | 1 | 2010 | 4244 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2003 | 1471 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 11106 | 0.010 |
Why?
|
| Genomics | 1 | 2010 | 5820 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 12796 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 15941 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2008 | 39117 | 0.000 |
Why?
|
| Young Adult | 1 | 2012 | 59207 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2003 | 64651 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 2003 | 80582 | 0.000 |
Why?
|